Finanzen von Milestone Pharmaceuticals Inc (MIST)MISTMilestone Pharmaceuticals Inc

Evaluating the bottom line, Milestone Pharmaceuticals Inc maintains a gross margin of 94.28%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4584.97%, while the net margin is -5118.78%. These profitability ratios, combined with a Return on Equity (ROE) of -35522.62%, provide a clear picture of how effectively MIST converts its operational activities into shareholder value.

In the context of the broader market, MIST competes directly with industry leaders such as GNLX and TNXP. With a market capitalization of $86.22M, it holds a leading position in the sector. When comparing efficiency, MIST's gross margin of 94.28% stands against GNLX's N/A and TNXP's 94.81%. Such benchmarking helps identify whether Milestone Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company has not generated revenue in the first three quarters of 2025, but it is projected to have total revenue of $1,546,000 in Q4 2025, with a gross margin of 100% expected in that quarter.